Leerink Swann Maintains an 'Outperform' on Medivation (MDVN); Number of Advantages Based on Labeling
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Brean Murray Carret & Co. Maintains a 'Buy' on Medivation (MDVN); Adjusting Numbers on Xtandi Approval
September 4, 2012 8:52 AM EDTBrean Murray Carret & Co. maintains a 'Buy' on Medivation (NASDAQ: MDVN) price target of $125.00 (from $105.00).
Analyst, MDVN's XTANDI (enzalutamide; MDV3100) was approved by the FDA on August 31 for patients with metastic castration-resistant prostate cancer who have previously received docetaxel, but we... More
Jefferies Reiterates a 'Buy' on Medivation (MDVN); Xtandi Approved Early
September 4, 2012 7:17 AM EDTJefferies reiterates a 'Buy' on Medivation (NASDAQ: MDVN) price target of $122.00 (from $113.00).
Analyst, Biren Amin, said, "Xtandi (enzalutamide) approval came ~3 months ahead of its November PDUFA date, and a slight positive on ~1 addl qtr of sales. The label was generally in-line... More
Medivation (MDVN) Up ~8% Following Halt for Xtandi Approval
August 31, 2012 4:01 PM EDTMedivation, Inc. (Nasdaq: MDVN) is now up 7.8 percent on the session after resumption.
Shares were up slightly before being halted for FDA approval of Xtandi for late stage prostate cancer.... More
Dendreon (DNDN) Hit After Medivation Wins FDA Approval for Prostate Cancer Drug
August 31, 2012 1:15 PM EDTDendreon Corp. (Nasdaq: DNDN) is seeing a little weakness here after the FDA approved Medivation (Nasdaq: MDVN) and Astellas XTANDI treatment for prostate cancer.
Shares of DNDN are down 1.6 percent.... More
FDA approves Medivation (MDVN) XTANDI for Prostate Cancer
August 31, 2012 1:11 PM EDTFDA approves Medivation (Nasdaq: MDVN) XTANDI treatment for prostate cancer (shares were halted)... More
